Moleculin Biotech, Inc. (NASDAQ:MBRX – Get Free Report) was the recipient of a large drop in short interest in February. As of February 28th, there was short interest totalling 1,080,000 shares, a drop of 50.9% from the February 13th total of 2,200,000 shares. Based on an average daily volume of 5,220,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 8.4% of the shares of the stock are sold short.
Analyst Upgrades and Downgrades
A number of equities research analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of Moleculin Biotech in a report on Monday, March 3rd. Maxim Group downgraded Moleculin Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th. Finally, StockNews.com assumed coverage on Moleculin Biotech in a report on Thursday. They set a “sell” rating on the stock.
View Our Latest Stock Analysis on MBRX
Moleculin Biotech Trading Down 2.6 %
About Moleculin Biotech
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
Featured Articles
- Five stocks we like better than Moleculin Biotech
- Stock Market Sectors: What Are They and How Many Are There?
- How to Build the Ultimate Everything ETF Portfolio
- How to Calculate Inflation Rate
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Best Stocks Under $5.00
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.